Financial releases

Interim 2017 results and business update

Business update Confirmation of the schedule of marketing authorisation filings

CROSSJECT receives €2.9M from Bpifrance as part of the PIAVE financing

CROSSJECT receives authorization to conduct Zeneo® Midazolam bioequivalence study

CROSSJECT boosts its US commercial development efforts

CROSSJECT unveils its strategic choices and new roadmap

CROSSJECT - AFPric STUDY: PATIENTS APPROVE NEEDLE-FREE INJECTION

CROSSJECT: Partnership agreement for ZENEO® Methotrexate in China with Xi’an Xintong Pharmaceutical Research

CROSSJECT secures €6.7 million in funding for the development of three new drugs

CROSSJECT enters into partnering agreement with Sayre Therapeutics to commercialize ZENEO® Methotrexate in India